Patents Assigned to Genentech
  • Methods and compositions for prognosis and treatment of cancers
    Patent number: 11236394
    Abstract: The invention provides methods of using expression levels of one or more immune cell gene signatures and/or combinations of immune cell gene signatures as selection criteria for selecting a patient having cancer for treatment with an immunotherapy. The invention further provides methods for selecting a patient having cancer who may benefit from a particular immunotherapy, such as an activating immunotherapy or a suppressing immunotherapy and administering to the patient the activating immunotherapy or suppressing immunotherapy to treat the cancer.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: February 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Luciana Molinero, Priti Hegde
  • Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators
    Patent number: 11236046
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: February 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Yanyan Chu, Steven Do, Anthony Estrada, Baihua Hu, Aleksandr Kolesnikov, Xingyu Lin, Joseph P. Lyssikatos, Daniel Shore, Vishal Verma, Lan Wang, Guosheng Wu, Po-wai Yuen
  • Fused ring compounds
    Patent number: 11236068
    Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: February 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Sushant Malhotra, Jianfeng Xin, Steven Do, Jack Terrett
  • HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20220023437
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: April 19, 2021
    Publication date: January 27, 2022
    Applicant: Genentech, Inc.
    Inventors: Yvonne CHEN, Mark DENNIS, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
  • Analysis and Visualization of Microbial Communities
    Publication number: 20220028549
    Abstract: In one embodiment, a software tool for performing microbiome analyses including accessing microbiome samples, generating a user interface associated with the software tool, wherein the user interface comprises input fields, and wherein each of the input fields corresponds to one or more of a phenotype or a feature associated with the microbiome samples, receiving user inputs to one or more of the input fields via the user interface of the software tool, generating a visualization comprising analysis results associated with the microbiome samples at the user interface, wherein the analysis results are generated based on the user inputs, and outputting an exportable report and software code comprising the generated visualization.
    Type: Application
    Filed: July 19, 2021
    Publication date: January 27, 2022
    Applicant: Genentech, Inc.
    Inventors: Joseph Nathaniel PAULSON, Janina REEDER
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20220024945
    Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: September 29, 2021
    Publication date: January 27, 2022
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG, Wei LI
  • Anti-B7-H4 antibodies and immunoconjugates
    Patent number: 11230600
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: January 25, 2022
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • METHODS FOR TREATMENT OF CANCER WITH AN ANTI-TIGIT ANTAGONIST ANTIBODY
    Publication number: 20220016243
    Abstract: The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.
    Type: Application
    Filed: January 26, 2021
    Publication date: January 20, 2022
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Catherine LAI, Janet LAU, Anthony Jongha LEE, Shi LI, Yvonne Gail LIN-LIU, Christina Jeanne MATHENY, Diana MENDUS, Raymond D. MENG, Anh NGUYEN DUC, Jilpa Bhupendra PATEL, Thinh Quang PHAM, Isabelle Anne ROONEY, Heather Blythe STEVENS, Sarah Marie TROUTMAN, Lijia WANG, Yulei WANG, Patrick Georges Robert WILLIAMS, Benjamin WU, Yibing YAN, Aijing ZHANG, Xiaosong ZHANG, Marcus Dale BALLINGER, Hila BARAK, Elizabeth Alexandra BENNETT, Marcela Lucia CASTRO, Edward Namserk CHA, Hui Min Phyllis CHAN, Stephen CHUI, Christopher Roland COTTER, Viraj Vinay DEGAONKAR, Barbara Jennifer GITLITZ, Tien HOANG, Kimberly Mayumi KOMATSUBARA
  • Method of treating asthma using an IL-13 antibody
    Patent number: 11226341
    Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: January 18, 2022
    Assignee: Genentech, Inc.
    Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
  • Method to improve virus filtration capacity
    Patent number: 11225513
    Abstract: The present invention relates to the field of protein purification. In particular, the invention concerns methods for increasing the filtration capacity of virus filters, by combined use of endotoxin removal and cation-exchange media in the prefiltration process.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: January 18, 2022
    Assignee: Genentech, Inc.
    Inventor: Amit Mehta
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
    Publication number: 20220008413
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: March 5, 2021
    Publication date: January 13, 2022
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother
  • PRODUCTION OF HETEROMULTIMERIC PROTEINS USING MAMMALIAN CELLS
    Publication number: 20220002386
    Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.
    Type: Application
    Filed: February 9, 2021
    Publication date: January 6, 2022
    Applicant: Genentech, Inc.
    Inventors: Justin SCHEER, Whitney SHATZ, Domingos NG
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20220002430
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: April 20, 2021
    Publication date: January 6, 2022
    Applicant: Genentech, Inc.
    Inventors: Camellia W. ADAMS, Andrew C. CHAN, Craig W. CROWLEY, Henry B. LOWMAN, Gerald R. NAKAMURA, Leonard G. PRESTA
  • PROCESSES FOR MAKING SERD TRICYCLIC COMPOUNDS HAVING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY
    Publication number: 20220002304
    Abstract: Provided herein are processes for the preparation of compounds useful in the treatment of cancer.
    Type: Application
    Filed: June 28, 2021
    Publication date: January 6, 2022
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: HAIMING ZHANG, JIE XU, GEORG WUITSCHIK, REMY ANGELAUD, SEBASTIAN HEROLD, ALFRED STUTZ, TOBIAS BRUETSCH, JOHANNES BURKHARD
  • TARGETED INTEGRATION OF NUCLEIC ACIDS
    Publication number: 20210403943
    Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins wherein those TI host cells have been subjected to supertransfection resulting in the random integration (RI) of exogenous nucleic acids encodes into their genome, as well as methods of producing and using said supertransfected TI host cells.
    Type: Application
    Filed: June 23, 2021
    Publication date: December 30, 2021
    Applicant: GENENTECH, INC.
    Inventors: Amy SHEN, Shahram MISAGHI, Cynthia Young LAM
  • PERTUZUMAB PLUS TRASTUZUMAB FIXED DOSE COMBINATION
    Publication number: 20210403599
    Abstract: The invention disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The final efficacy and safety data for the FeDeriCa clinical trial, United States Prescribing Information (USPI) (including home-use) methods, and primary analysis of the PHranceSCa clinical trial are disclosed and claimed.
    Type: Application
    Filed: June 28, 2021
    Publication date: December 30, 2021
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Tanja Badovinac-Crnjevic, Yu Chien Fredriksson, Sarah Heeson, Ihsan Hamdi Nijem, Whitney Paige Kirschbrown, Eleonora Restuccia
  • TARGETED INTEGRATION OF NUCLEIC ACIDS
    Publication number: 20210403953
    Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins wherein those TI host cells have been subjected to supertransfection resulting in the random integration (RI) of exogenous nucleic acids encodes into their genome, as well as methods of producing and using said supertransfected TI host cells.
    Type: Application
    Filed: June 18, 2021
    Publication date: December 30, 2021
    Applicant: GENENTECH, INC.
    Inventors: Amy SHEN, Shahram MISAGHI
  • Macrocyclic broad spectrum antibiotics
    Patent number: 11208387
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: December 28, 2021
    Assignee: Genentech, Inc.
    Inventors: Michael F. T. Koehler, Peter Andrew Smith, Dana Winter, Boubacar Sow, Claudio Sturino, Guillaume Pelletier, Jonathan Boudreault
  • Methods of administering anti-fibrotic therapy
    Patent number: 11207304
    Abstract: The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: December 28, 2021
    Assignee: GENENTECH, INC.
    Inventors: Lin Pan, Dorothy Sze-Wing Cheung, Jeffrey Mark Harris, Indiana Strombom
  • CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
    Publication number: 20210395268
    Abstract: The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: January 25, 2021
    Publication date: December 23, 2021
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE